Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 4/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | PARP10 | Q53GL7 | 3/20 | 0.40 |
| ▸ | PARP15 | Q460N3 | 2/20 | 0.40 |
| ▸ | RARA | P10276 | 1/20 | 0.40 |
| ▸ | RARB | P10826 | 1/20 | 0.40 |
| ▸ | LSS | P48449 | 2/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
| ▸ | PPARD | Q03181 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.39 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22286220 | 0.84 | MAOB (0.44) | MAOBMAOAPARP10PARP15RARA | |
| SCHEMBL3083648 | 0.83 | RARA (0.56) | MAOBMAOARARARARBFFAR1 | |
| SCHEMBL3066860 | 0.83 | MAOB (0.46) | MAOBMAOAPARP10PARP15RARA | |
| SCHEMBL5262015 | 0.82 | THRA (0.51) | MAOBPPARGPPARDFFAR4 | |
| SCHEMBL5057136 | 0.82 | KDM4E (0.53) | MAOBMAOAPARP10PARP15FFAR1 | |
| SCHEMBL3079256 | 0.82 | PARP10 (0.58) | MAOBMAOAPARP10PARP15RARA | |
| SCHEMBL5260336 | 0.82 | MAOB (0.62) | MAOBMAOAPPARD | |
| SCHEMBL3085429 | 0.81 | POLB (0.52) | MAOBMAOAPARP10PARP15RARA | |
| SCHEMBL20491473 | 0.80 | KCNH2 (0.44) | MAOBMAOAPARP10PARP15PPARG | |
| SCHEMBL2100809 | 0.78 | CPS1 (0.56) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1268478-B1 | PHENYL-SUBSTITUTED IMIDAZOPYRIDINES | ORTHO MCNEIL PHARM INC (US) | 2007-05-02 | — | — | EP | disclosed |
| US-7199117-B2 | Phenyl-substituted imidazopyridines | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2007-04-03 | — | — | US | disclosed |
| US-7087757-B2 | Phenyl-substituted imidazopyridines | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2006-08-08 | — | — | US | disclosed |
| US-7041827-B2 | Phenyl-substituted imidazopyridines | BREITENBUCHER J GUY | 2006-05-09 | — | — | US | disclosed |
| US-7041828-B2 | Phenyl-substituted imidazopyridines | BREITENBUCHER J GUY | 2006-05-09 | — | — | US | disclosed |
| US-6908929-B2 | Phenyl-substituted imidazopyridines | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2005-06-21 | — | — | US | disclosed |
| US-20050090523-A1 | 2-(substituted phenyl)imidazo[1,2-a]pyridine compounds; use to treat disorders mediated by the histamine H3 receptor such as sleep disorders, attention deficit hyperactivity disorder, or Alzheimer's disease; 2-[4-[3-(Piperidino)propylamino]phenyl]-8-methylimidazo[1,2-a]pyridine for example | BREITENBUCHER J G (US) | 2005-04-28 | — | — | US | disclosed |
| US-20050085502-A1 | Phenyl-substituted imidazopyridines | BREITENBUCHER J G (US) | 2005-04-21 | — | — | US | disclosed |
| US-20050085501-A1 | Phenyl-substituted imidazopyridines | BREITENBUCHER J G (US) | 2005-04-21 | — | — | US | disclosed |
| US-20050049277-A1 | Phenyl-substituted imidazopyridines | BREITENBUCHER J GUY (US) | 2005-03-03 | — | — | US | disclosed |
| US-20050043348-A1 | Phenyl-substituted imidazopyridines | BREITENBUCHER J GUY (US) | 2005-02-24 | — | — | US | disclosed |
| EP-1268478-A2 | PHENYL-SUBSTITUTED IMIDAZOPYRIDINES | Ortho McNeil Pharmaceutical, Inc. (US) | 2003-01-02 | — | — | EP | disclosed |
| US-20020006934-A1 | Phenyl-substituted imidazopyridines | ORTHO MCNEIL PHARMACEUTICAL, INC. | 2002-01-17 | — | — | US | disclosed |
| WO-2001074815-A2 | PHENYL-SUBSTITUTED IMIDAZOPYRIDINES | ORTHO MCNEIL PHARMACEUTICAL, INC. (US) | 2001-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043348-A1 | Phenyl-substituted imidazopyridines | AADAC, DPP4, DPP3 | MAOB 429/4885MAOA 277/4885PARP10 903/4885 |
| US-20050085502-A1 | Phenyl-substituted imidazopyridines | AADAC, DPP4, DPP3 | MAOB 429/4885MAOA 277/4885PARP10 903/4885 |
| US-20050085501-A1 | Phenyl-substituted imidazopyridines | AADAC, DPP4, DPP3 | MAOB 429/4885MAOA 277/4885PARP10 903/4885 |
| US-20050049277-A1 | Phenyl-substituted imidazopyridines | AADAC, DPP4, DPP3 | MAOB 429/4885MAOA 277/4885PARP10 903/4885 |
| US-20050090523-A1 | 2-(substituted phenyl)imidazo[1,2-a]pyridine compounds; use to treat disorders mediated by the histamine H3 receptor such as sleep disorders, attention deficit hyperactivity disorder, or Alzheimer's disease; 2-[4-[3-(Piperidino)propylamino]phenyl]-8-methylimidazo[1,2-a]pyridine for example | HRH3, HRH4, HTR2C | MAOB 193/4885MAOA 67/4885PARP10 1899/4885 |
| US-20020006934-A1 | Phenyl-substituted imidazopyridines | AADAC, DPP4, DPP3 | MAOB 429/4885MAOA 277/4885PARP10 903/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.